MB closer to IVF product launch with $12.5m series B
This article was originally published in Clinica
Executive Summary
Molecular Biometrics (MB) is stepping up efforts for the global launch of ViaMetrics-E, its lead product for enhancing in vitro fertilisation outcomes, after raising $12.5m in series B financing. The round was led by new investor Atlas Venture, with contributions from existing shareholders Safeguard Scientifics and Oxford Bioscience Partners. The funds will enable the company to expand its commercial operations for the product launch outside the US, implement manufacturing and product enhancements and complete its ongoing FDA clinical study. ViaMetrics-E uses metabolomics, a complex scientific process, to identify viable embryos having the greatest reproductive potential, thereby improving pregnancy rates in IVF while reducing the risks of multiple births, says Norwood, Massachusetts-based MB.